Publication
A Phase 1 Trial of Duvelisib and Oral Azacitidine in Relapsed/Refractory T-Cell Lymphoma.
Hayder Saeed, Melanie Mediavilla Varela, Eva Sahakian, Mahrukh Naqvi, Qianxing Mo, Ling Zhang, Rikesh Makanji, Yumeng Zhang, Ning Dong, Leidy Isenalumhe, Sameh Gaballa, Julio Chavez, Bijal Shah, Celeste Bello, Lubomir Sokol, Javier Pinilla-Ibarz
- Source
- PubMed
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260911-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Mature T-cell lymphomas (TCL) are aggressive malignancies with limited effective therapies. Duvelisib (DUV), a dual inhibitor of PI3K-δ and PI3K-γ, has shown promising activity in TCL. Azacitidine (AZA), a hypomethylating agent, has demonstrated efficacy in TCL and may enhance the activity of PI3K…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT05065866registry_reference1.00
Registered trialsNCT05065866
Curated evidence
Evidence citing this paper (0)
Data not yet available